VYD2311

VYD2311 is a novel monoclonal antibody (mAb) candidate developed by Invivyd for the prevention of COVID-19. It is designed to provide strong protection (70–90%) against symptomatic COVID-19, with less frequent dosing (once or twice annually) via intramuscular or subcutaneous administration. Unlike vaccines, VYD2311 does not activate the subject's immune system directly. The antibody was engineered using Invivyd’s proprietary technology platform through serial molecular evolution to optimize neutralization of contemporary SARS-CoV-2 variants. Mechanistically, it targets and inhibits the SARS-CoV-2 spike protein receptor binding domain, thereby preventing viral attachment to the human ACE2 receptor on host cells. Preclinical and early clinical data indicate that VYD2311 has a favorable safety profile and superior in vitro neutralization potency—approximately 17-fold greater than pemivibart—against current virus lineages[2][6][8]. The drug is currently in Phase 1/2 clinical trials.

Other names

VYD2311 single-doseVYD-2311 single-doseVYD 2311 single-dose